

National Organization for Rare Disorders, Inc.®

NORD • 55 Kenosia Avenue, P.O. Box 1968 • Danbury, CT 06813-1968

Tel: 203-744-0100 • FAX: 203-798-2291

TDD (for hearing impaired) (203) 797-9590

<http://www.rarediseases.org> • e-mail: orphan@rarediseases.org

January 12, 2007

1577 7 JAN 19 19:30



... out of the darkness,
into the light ...

Division of Dockets Management (HFA-305)
Food & Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

RE: Docket No. 2006N-0062
RIN 0910-AF14

Expanded Access to Investigational Drugs
for Treatment Use: Proposed Rule

Dear Sir or Madam:

The National Organization for Rare Disorders (NORD) is pleased that the FDA has issued a Proposed Rule to clarify the mechanisms under which patients may have access to investigational drugs outside of controlled clinical trials. NORD is a national non-profit voluntary health agency representing an estimated 25 million Americans with rare "orphan" diseases. Treatments for these disorders are generally known as "orphan drugs," and they are usually the first and only treatments for very serious and life-threatening diseases.

The Rule

The proposed rule suggests that the term "Expanded Access" should be used to describe a group of three methodologies that would allow access to investigational drugs: The first would allow access to individuals, or a small group of individuals, who have no other available treatment for their serious or life-threatening disease; the second would allow access by an intermediate size population; and the third (Treatment IND) would allow broad access for the largest populations.

We are pleased that FDA recognizes that in the past, access to investigational drugs had favored cancer and HIV, while people with other serious and life-threatening diseases have felt ignored. Clarifying the rules based on population size instead of diagnosis is logical and equitable, as long as it does not interfere with the conduct of controlled clinical trials. We also concur that a basic stipulation for any expanded access program should be a mandatory listing on the Clinicaltrials.gov Website.

2006N-0062

C4

NATIONAL MEMBER ORGANIZATIONS

Alagille Syndrome Alliance
Alpha 1 Association
Alpha 1 Foundation
American Brain Tumor Association
American Porphyria Foundation
American Stryngomyelia Alliance Project
Aplastic Anemia & MDS International Foundation, Inc.
Association for Glycogen Storage Disease
Association of Gastrointestinal Motility Disorders, Inc. (AGMD)
Association for Frontotemporal Dementias (AFTD)
Batten Disease Support & Research Association
Benign Essential Blepharospasm Research Foundation
Charcot-Marie Tooth Association
Children's Tumor Foundation
Chromosome 18 Registry Research Society
Cicatrical Alopecia Research Foundation (CARF)
Cleft Palate Foundation
Cornelia De Lange Syndrome Foundation
Cystinosis Foundation, Inc.
Dystrophic Epidermolysis Bullosa Research Association of America-DEBRA
Dysautonomia Foundation, Inc.
Dystonia Medical Research Foundation
Ehlers Danlos National Foundation
Erythromelalgia Association
Families of Spinal Muscular Atrophy
Foundation For Fighting Blindness
Foundation for Ichthyosis and Related Skin Types
GBS/CIDP Foundation International
Genetic Alliance
Hereditary Colon Cancer Association
Hereditary Disease Foundation
HHT Foundation International, Inc.
Histiocytosis Association of America
Huntington's Disease Society of America
Immune Deficiency Foundation
International FOP Association, Inc.
International Rett Syndrome Association
Interstitial Cystitis Association
Kennedy's Disease Association
LAM Foundation
Lowe Syndrome Association, Inc.
Mastocytosis Society, Inc.
Meckel Syndrome Foundation
Mucopolidiosis Type IV Foundation, Inc.
Myasthenia Gravis Foundation of America, Inc.
Myositis Association
Narcolepsy Network, Inc.
National Adrenal Disease Foundation
National Alopecia Areata Foundation
National Ataxia Foundation
National Foundation for Ectodermal Dysplasias
National Fragile X Foundation
National Hemophilia Foundation
National Kidney Foundation
National Marfan Foundation
National MPS Society, Inc.
National Multiple Sclerosis Society
National PKU News
National Spasmodic Torticolis Association
National Tay Sachs & Allied Diseases Association
National Urea Cycle Disorders Foundation
Neurofibromatosis, Inc.
Osteogenesis Imperfecta Foundation
Paget Foundation for Paget's Disease of Bone & Related Disorders
Parkinson's Disease Foundation, Inc.
Platelet Disorder Support Association
Prader Willi Syndrome Association, USA
Pulmonary Hypertension Association
Reflex Sympathetic Dystrophy Syndrome Association
Sarcoma Foundation of America
Scleroderma Foundation
Stevens Johnson Syndrome Foundation
Sturge-Weber Foundation
The Oxalosis and Hyperoxaluria Foundation
Tourette Syndrome Association
Trigeminal Neuralgia Association
United Leukodystrophy Foundation
United Mitochondrial Disease Foundation
Vasculitis Foundation
Vestibular Disorders Association, VEDA
VHL Family Alliance
Williams Syndrome Association
Wilson's Disease Association

Associate Member Organizations

Children's PKU Network
Chromosome Deletion Outreach Inc.
Chronic Granulomatous Disease Association
CLIMB
Coalition for Pulmonary Fibrosis
Consortium of Multiple Sclerosis Centers
Contact A Family
Cushing Support & Research Foundation, Inc.
Cutis Laxa Internationale
EURORDIS
Family Caregiver Alliance

Family Support Network of North Carolina
Fibromuscular Dysplasia Society of America
Freeman-Sheldon Parent Support Group
GOLD, Global Organization for Lysosomal Diseases
Hereditary Neeropathy Foundation
Hydrocephalus Association
Incontinentia Pigmenti International Foundation
Klippel-Trenaunay Support Group
Les Turner ALS Foundation, Ltd.
Locks of Love
Metarheostosis Association

Mercy Medical Airlift
National Lymphedema Network, Inc.
National Niemann-Pick Disease Foundation
National Organization for Albinism and Hypopigmentation, NOAH
National Spasmodic Dysphonia Association
Organic Acidemia Association
Osteoporosis and Related Bone Diseases National Resource Center
Parent to Parent New Zealand, Inc.
Recurrent Respiratory Papillomatosis Foundation

Sarcoid Networking Association
Shwachman - Diamond Syndrome Foundation
Society for Progressive Supranuclear Palsy, Inc.
Sotos Syndrome Support Association
Syncope Trust & Reflex Anoxic Seizures Assn. (STARS)
Taiwan Foundation for Rare Disorders
Wisconsin Chronic Fatigue Syndrome Association
Associations are joining continuously. For newest listing, please contact the NORD office.

Dedicated to Helping People with Orphan Diseases

Limitations

Unfortunately, FDA admits that it cannot force sponsors to offer expanded access to patients outside of clinical trials. Thus, expanded access may remain an unfulfilled dream to patients who will know the expanded access mechanism exists, yet will still be unable to obtain the drug.

We agree that risks and possible benefits must be well characterized before access to an investigational drug can be granted, and all human subject protections must be in place. Since the great majority of investigational drugs do not achieve marketing approval because they are either unsafe or ineffective, FDA must do its utmost to prevent a "therapeutic misperception" that experimental drugs will definitely help desperate patients who have no other treatment options. Patients should be counseled, and informed consent documents must reflect that they cannot expect to personally benefit from the drug, but the knowledge gained from the experiment will help other patients in the future.

Expanded access should be permitted no sooner than the completion of Phase II trials so that risks and potential benefits can be characterized from the results of preceding trials. The data from Phase II trials must be compelling before access is allowed. Otherwise Phase II trials should be fully enrolled or completed before broader access is permitted, and only if relative safety and effectiveness is probable.


We are pleased that the agency has made provision for small populations such as rare diseases, drugs not approved in the USA but used in other countries, and drug shortages. However, the proposed rule does not mention an element of the original Treatment IND regulation: The ability of companies to charge patients for the cost of the investigational drug.

The original IND regulation allowed companies to recoup their development costs by charging patients for the cost of the drug without a profit. Unfortunately, we learned from those experiences that in general, health insurance and Medicare/Medicaid will not pay for investigational drugs except for Group C cancer medications. The National Cancer Institute designates Group C drugs, but no other class of drugs is categorized this way.

Therefore, if companies are permitted to charge patients for an investigational drug under any expanded access scenario, only the wealthy will have access. This is a very serious problem, and we understand that FDA may be hesitant to address it. We would like to see a requirement that companies choosing to charge for investigational drugs put aside a quantity of the drug for needy patients who cannot afford to pay. There is no other equitable way to address the issue of reimbursement, nor to require insurers to pay. The more expensive a drug or biologic is, the less likely that reimbursement will be available. Additionally, if lab tests or imaging procedures are required during therapy, and if insurance will not pay, sponsors should be required to cover those costs to prevent patients from skipping those tests or procedures.

We hope these comments are helpful. Again, we thank the agency for the proposed rule, which will make expanded access programs more understandable and uniform.

Very truly yours,


Abbey S. Meyers
President

ASM:aa